

Launch of the SyncroPatch 384i – the next level of automated patch clamp innovation

Munich, Germany, June 21st 2019: Nanion is pleased to announce the launch of the SyncroPatch 384i. This new giga-ohm seal HTS automated patch clamp platform provides effortless ion channel screening coupled with unmatched flexibility, ease-of-use and reliability. The new SyncroPatch 384i builds on the success of the SyncroPatch 384PE, which has been globally established as the preferred automated patch clamp workhorse in Pharma, Biotech, CRO and academia. The SyncroPatch 384i is based on the newly introduced and state-of-the art Biomek i5 liquid handler and will be ready for sale from July 1st.

In 2013, the SyncroPatch 384PE was launched as the first automated patch clamp instrument capable of delivering giga-ohm seal-quality data in a 384-well plate format. Globally acknowledged as the preferred automated patch clamp system, the SyncroPatch 384PE has enabled a revolution in ion channel drug discovery and safety pharmacology by making it possible to screen large compound libraries at a significantly lower cost than earlier generations of automated patch clamp devices.

Following a decade of collaboration between Beckman Coulter Life Science and Nanion Technologies, the SyncroPatch 384i has been developed with the objective to significantly improve the user experience and screening efficiency.

The new Biomek i5 liquid handler greatly improves experimental flexibility, ease-of-use and reliability and is the perfect environment for Nanion's proprietary hardware and software which in the new system are adding new and valuable features to improve data generation and analysis.

The great flexibility and low running costs makes the SyncroPatch 384i equally applicable in all phases of pre-clinical drug discovery.

Though the SyncroPatch 384i will completely substitute the SyncroPatch 384PE, both systems will continue to receive superior technical and application support from our large team of application scientists and field service engineers.

The SyncroPatch 384i will be ready for sale from July 1st, but Nanion has already started taking orders for the new system.



"Pharmaceutical companies and CROs are driving the need for higher throughput campaigns on various targets while researchers have smaller, and more diverse development projects that need higher flexibility. The SyncroPatch 384i is ideally suited for both purposes" says

Dr. Niels Fertig, CEO and founder of Nanion Technologies.

About Nanion Technologies:

Nanion Technologies is a leading provider of instrumentation for ion channel drug discovery and screening. Founded in 2002, Nanion has grown over the last 17 years to a company with over 100 employees worldwide. With headquarters in Munich, Germany, Nanion has subsidiaries in the USA, Japan, China and Denmark, as well as distribution partners in seven other countries.

Nanion's team has developed and successfully established four generations of automated patch clamp instruments for sophisticated and high throughput applications in ion channel research and drug discovery (Port-a-Patch, Patchliner and SyncroPatch product



families). Further product lines are for cell monitoring and cardiotoxicity screening (CardioExcyte 96), for parallel bilayer recordings (Orbit family), and for parallel membrane transporter protein recordings (SURFE²R).

For more information, please visit www.nanion.de

Contact:

Dr. Niels Fertig, CEO, Nanion Technologies GmbH,
Munich, Germany

Phone: +49 89 2190 95-072

Email: Niels.Fertig@nanion.de

Frank Henrichsen, Director of Global Sales, Nanion
Technologies GmbH, Munich, Germany

Phone: +45 40 87 29 - 17

Email: Frank.Henrichsen@nanion.de

About Beckman Coulter:

Beckman Coulter Life Sciences' global leadership and world-class service and support delivers instrument systems, reagents and services to improve workflow and outcomes for researchers in academic and commercial life sciences laboratories, enabling discoveries in biology-based research and development, and solutions for bioprocessing. A leader in centrifugation and flow cytometry, Beckman Coulter also has brought to market innovations in capillary electrophoresis, particle characterization and laboratory automation. Its products are used to further important areas of scientific investigation, including genomics and proteomics.

For more information, please visit www.beckman.com

Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. All rights reserved.

Press Contact:

Beckman Coulter Public Relations

Phone: +1 (561) 714-7826 Hillary Hunter, Public Relations

Email: hillaryhunter@beckman.com